A Randomized Phase III Trial of Brentuximab Vedotin (bv) for De Novo High-Risk Classical Hodgkin Lymphoma (chl) in Children and Adolescents - Study Design and Incorporation of Secondary Endpoints in Children's Oncology Group (COG) AHOD1331
Klinische Pädiatrie(2020)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined